nasopharyngeal Carcinoma
Conditions
Interventions
Case series:capecitabine monotherapy
Sponsors
Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed WHO type II or III nasopharyngeal carcinoma; 2. Initial treatment adopted radical radiotherapy with or without chemotherapy; 3. Pathologically confirmed nasopharyngeal tumor and / or cervical lymph node residual at the time of 3-6 months after the initial treatment; and / or nasopharyngeal + neck MRI considered tumor residual at the time of 3 months after the initial treatment and two or more imaging expert diagnosis of nasopharyngeal tumor and / or cervical lymph node residual after a month waiting; 4. Not suitable for local treatment, mainly referring to anti-tumor treatment, including surgery and radiotherapy; 5. Male or female, 18–70 years old; 6. Karnofsky performance scoring >=70; 7. No severe heart, lung, liver, kidney and other important organ dysfunction; 8. normal renal and hepatic function: ALT and AST = 60 mL/min; Adequate bone marrow function: absolute white blood cell count >4.0x10^9/L, neutrophil >2.0x10^9/L, hemoglobin >90 g/L, platelets >100x10^9/L); 9. Written informed consent with exact date obtained from the individual patients before certain proposed step.
Exclusion criteria
Exclusion criteria: 1. Detection of distant metastasis before treatment; 2. Pregnancy or breast feeding; 3. Informed consent refusal; 4. Patients unable to be followed up regularly; 5. Accompanied by serious uncontrollable infection or medical diseases; 6. Inadequate organ function and cannot tolerate chemotherapy; 7. Conditions that may adversely affect pharmacokinetics: such as psychiatric disorders, central nervous system disorders, chronic diarrhea, ascites and hydrothorax; 8. Long-term treatment with immune-suppressor after organ transplantation; 9. Other malignancy before inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year overall survival;Drug safety;Drug safety;objective response rate;living quality; | — |
Countries
China
Contacts
Public ContactLv Xing
Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University
Outcome results
None listed